Amarin Corporation

Amarin Corporation Tangible Book Value per Share

The Tangible Book Value per Share of Amarin Corporation (AMRN) as of Nov 19, 2026 is 20.85 USD. In the previous year, Tangible Book Value per Share was 22.64 USD — a change of -7.93% (lower).

Tangible Book Value per Share

20.85USD

YoY

-7.93%

Last updated:

Tangible Book Value per Share of Amarin Corporation is 2025 20.85 USD. Tangible Book Value per Share of Amarin Corporation was 2024 22.64 USD. It decreases by -7.93% lower compared to the previous year.

The Amarin Corporation Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
6.98 USD
Jan 1, 2019
28.58 USD
Jan 1, 2020
29.58 USD
Jan 1, 2021
31.02 USD
Jan 1, 2022
27.64 USD
Jan 1, 2023
25.68 USD
Jan 1, 2024
22.64 USD
Jan 1, 2025
20.85 USD
The Amarin Corporation Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
20.85USD-7.93%
22.64USD-11.83%
25.68USD-7.10%
27.64USD-10.89%
31.02USD+4.87%
29.58USD+3.50%
28.58USD+309.42%
6.98USD-297.86%
-3.53USD+309.90%
-0.86USD-87.11%
-6.68USD+40.63%
-4.75USD-8.06%
-5.17USD+152.16%
-2.05USD+4,535.07%
-0.04USD-97.67%
-1.90USD-2,936.98%
0.07USD-99.00%
6.66USD-32.94%
9.92USD-84.48%
63.96USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Tangible Book Value per Share of Amarin Corporation is 20.85 USD in 2025.

Tangible Book Value per Share of Amarin Corporation changed from 22.64 USD to 20.85 USD, representing a -7.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Amarin Corporation

All Key Metrics — Amarin Corporation